TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced the following Executive Comittee Standing Members effective from April 1, 2021.
Executive Committee 1 Standing Members (as of April 2021)
Under Corporate Strategic Plan 2018, Astellas highlights 'Evolving How We Create VALUE with Focus Area Approach' as one of its strategic goals. The goal of the Focus Area approach is to create innovative pharmaceuticals for diseases with high unmet medical needs by identifying unique combinations of biologies with clear disease relevance and versatile modalities / technologies. Chief Scientific Officer (CScO) is newly assigned for accelerating the Focus Area approach by strengthening research activities. Yoshitsugu Shitaka, who is currently the President of Astellas Institute for Regenerative Medicine and has contributed significantly to the development of the cell therapy, will be appointed to CScO, and will also serve as the President, Drug Discovery Research. Furthermore, Chief Business Officer (CBO) is newly assigned to lead and supervise the execution of Corporate Strategic Plan starting in Fiscal Year 2021. Percival Barretto-Ko, who has demonstrated a strong track record of robust leadership as President of United States Commercial will be appointed to CBO.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
(C) 2021 Electronic News Publishing, source ENP Newswire